Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of SCIB1, a DNA Immunotherapy, in the Treatment of Patients With Malignant Melanoma

NCT01138410 is registered in ClinicalTrials.gov with Scancell Ltd as lead sponsor.

NCT NCT01138410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01138410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of SCIB1, a DNA Immunotherapy, in the Treatment of Patients With Malignant Melanoma
Lead sponsor
Scancell Ltd
Phase
Phase 1/2
Overall status
Terminated
Start date
May 31, 2010
Completion date
July 7, 2017
Enrollment
35 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma